India, March 26 -- Lactulose is US FDA-approved and has long been recognised as a treatment for chronic constipation

Cadila Pharmaceuticals, a pioneer in healthcare innovation, has launched Cadilose, an advanced Lactulose formulation designed to effectively manage constipation and hepatic encephalopathy (HE). The latest addition to its gastrointestinal portfolio reaffirms the company's commitment to advancing patient care and improving quality of life through pharmaceutical innovation.

Cadilose is a disaccharide-based osmotic laxative, synthesised from galactose and fructose, which increases water retention in the intestines and promotes smooth bowel movements. It also functions as a prebiotic, encouraging the growth of beneficial gut b...